Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

See how small bits of non-coding RNA target mRNA for destruction and ... to various diseases by injecting manufactured dsRNA or antisense siRNA strands into cells (Whalley, 2006).

circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications ...

RNAi is a powerful tool for studying gene function and has potential applications in therapeutics. RNA-based therapeutics, such as siRNAs, antisense oligonucleotide, and mRNA vaccines, harness the ...

A recent study by researchers from Nanyang Technological University identified Fanconi anemia complementation group M (FANCM) as a crucial regulator of alternative lengthening of telomere (ALT), ...